The CALLY Index for Unresectable or Recurrent Gastric Cancer Treated With Nivolumab: A Multicenter Retrospective Study. (PubMed, J Gastric Cancer) - Oct 9, 2026 - "The pretreatment CALLY index was an independent prognostic biomarker for both OS and PFS in patients with unresectable or recurrent gastric cancer receiving third- or later-line nivolumab monotherapy. By integrating the C-reactive protein levels, albumin levels, and lymphocyte counts, the CALLY index may serve as a practical tool for pretreatment risk stratification in this setting."
Biomarker • Journal • Retrospective data • Gastric Cancer • Oncology • Solid Tumor • CRP
|
|
Fumiaki Yano; Kazuhide Sato; Ken Eto; Kenji Takeshita; Mizuki Fukuda; Motohiro Shionozaki; Muneharu Fujisaki; Naoko Fukushima; Yoshitaka Ishikawa; Yuta Takano
|